Allogeneic stem cell therapy allows "off the shelf" cells ... In the likely event of an EU licence for the therapy, Takeda will pay a 15 million euro fee to Tigenix. Apart from affecting the ...
Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...
Global Cell Therapy market is driven by increasing demand for advanced therapies in oncology, regenerative medicine, and immunology. The market's expansion is also fueled by continuous innovations in ...
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities ... including a midstage CD19 CAR-NK cell therapy, a small molecule known as subasumstat and a peptide agonist ...
Fresenius Kabi Receives FDA 510 (k) Clearance for Adaptive Nomogram, Enhancing Plasma Collection Efficiency with the Aurora ...
The two companies have been working together since 2017, with Takeda pledging $100 million to help GammaDelta advance its cell therapy platform as part of a "build-to-buy" arrangement. The ...
14d
Japan’s market growth accelerates through dynamic clinical partnerships, biologic breakthroughs, and automated facilities. Japanese firms confront shifting priorities in specialized therapies, ...
The CAR-NK cell therapy ‘TAK-007’ developed by Takeda Pharmaceutical eliminates cancer cells. /Courtesy of Takeda "Momentum for developing therapies... expectations for expansion of the ...
The global enzyme replacement therapy market size was valued at USD 10.12 billion in 2024 and is projected to grow from USD 11.35 billion in 2025 to reach USD 21.29 billion by 2033, exhibiting a CAGR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback